LB Pharmaceuticals Inc LBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.24M | 17.71M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.24M | 45.08M | -- | -- | -- |
| Operating Income | -92.24M | -45.08M | -- | -- | -- |
| Income Before Tax | -85.68M | -38.95M | -- | -- | -- |
| Income Tax Expenses | 1.00K | 1.00K | -- | -- | -- |
| Earnings from Continuing Operations | -85.69 | -38.95 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.69M | -38.95M | -- | -- | -- |
| EBIT | -92.24M | -45.08M | -- | -- | -- |
| EBITDA | -91.89M | -44.76M | -- | -- | -- |
| EPS Basic | -3.45 | -15.31 | -- | -- | -- |
| Normalized Basic EPS | -2.09 | -9.55 | -- | -- | -- |
| EPS Diluted | -3.45 | -15.31 | -- | -- | -- |
| Normalized Diluted EPS | -2.09 | -9.55 | -- | -- | -- |
| Average Basic Shares Outstanding | 89.59M | 59.81M | -- | -- | -- |
| Average Diluted Shares Outstanding | 89.59M | 59.81M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |